Inhaled Drug Development

Inhaled Drug Development
Product Description

Quotient has a 30 year track record in the development and manufacturing of inhaled drug products. We have experience across a range of drug delivery platforms including dry powder inhalers (DPIs) and solutions/suspensions for inhalation. With integrated capabilities and vast knowledge of nasal and pulmonary delivery, we help our clients accelerate their molecules from first-in-human, through to proof-of-concept and into full development.

Integrated capabilities and expertise for nasal and pulmonary delivery
Our extensive expertise and capabilities for nasal and pulmonary delivery include:
- Pre-formulation and API characterization
- Formulation and process development
- Inhaled device evaluation and selection
- Clinical manufacturing and supply (Phase I-III)
- Clinical pharmacology assessments


We have a wide range of processing and analytical equipment to support the development and manufacture of inhaled drug products:
- Spray drying
- Micronization
- Blending and encapsulation
- Aerosol characterization

QUOTIENT SCIENCES LIMITED

  • GB
  • 2017
    On CPhI since
  • 500 - 999
    Employees
Specifications
  • Supplied from
    United Kingdom; United States

QUOTIENT SCIENCES LIMITED

  • GB
  • 2017
    On CPhI since
  • 500 - 999
    Employees

More Products from QUOTIENT SCIENCES LIMITED

  • Candidate Selection - Integrated Programs

    Product Candidate Selection - Integrated Programs

    Selecting the right molecules for development - Quickly identify the best drug candidates. Knowing what it takes to develop a successful drug, we help clients select the best molecules for development. Our unique integration of scientific capabilities enables us to provide a complete assessment of molecule “developability”. Through this, we quickly identify the best drug candidates – the potential winners – mitigating risks for our clients and shortening the time to reach the clinic.

  • Early Stage Development - Integrated Programs

    Product Early Stage Development - Integrated Programs

    Accelerating molecules through to proof-of-concept - Simplify early development and accelerate to Proof-of Concept.Proof-of-concept (POC) is a key milestone in the development of a new drug candidate. We understand the transition to POC needs to be fast and cost-effective.With fully integrated capabilities from first-in-human testing to seamless drug product supply for patient trials, we simplify early development and accelerate molecules through to POC.

  • Late Stage Development - Integrated Programs

    Product Late Stage Development - Integrated Programs

    .Accelerating products through to commercial manufacture - Speed the journey from proof-of-concept to commercial launch. The journey from proof-of-concept to commercial launch can be complex. Speed is critical but it shouldn’t come at the expense of product quality. Creating patient-centric formulations and scaling up from pilot-scale to commercial manufacturing, we help clients turn promising molecules into successful drug products.

  • Drug Substance

    Product Drug Substance

    Our streamlined approach to developing drug substance has been shown to reduce manufacturing costs by 50% from preclinical to Phase I.  To best support our customer’s needs, we have made significant investments in technologies and equipment to meet the increasing demand for complex small-scale drug substance manufacture. With more than 40 years of experience in synthetic organic chemistry coupled with extensive expertise in flow chemistry, synthetic biology and biocatalysis, we can optimize manufacturing processes and save months of development time for our customers. 

    - Process Research and Development- Solid State Services

    - Capabilities include:
    - Salt Selection:
    - Polymorph Screening- Amorphous Dispersions- Crystallization Development
    - Solid State Characterization:
    - X-Ray powder diffraction (XRPD)
    - Theral Analysis (DSC, TGA)
    - Hygroscopy (DVS)Hot stage microscopy
    - Particle size distribution and particle enumeration
    - Surface Area
    - Solution and Solid State NMRFT-IR
    - Dissolution/disintegration
  • Formulation Development

    Product Formulation Development

    Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,000 molecules at all stages of drug development.

    - Formulations design 
    - Pre-formulation screening
    - First-in-human
    - Solubility enhancement 
    - Modified release
    - Analytical Services 
    - Process optimization & scale-up 
    - Gamma scintigraphy
  • Clinical Trial Manufacturing

    Product Clinical Trial Manufacturing

    Understanding that early phase clinical testing is a pivotal milestone in the development of your drug product, Quotient offers a clinical trial manufacturing, testing and certification service designed to meet your individual requirements. Our innovative method of building integrated GMP and GCP programs provides you with a streamlined, flexible approach to drug product supply that reflects your clinical study design and timeline. We understand the time and cost pressures you face during early phase evaluation and work with you to ensure a rapid, seamless path from development to clinical trial supply.We understand your need to move rapidly through clinical development and have built the capability to efficiently scale up drug product manufacturing processes to meet the demands of global clinical and patient supply requirements.
    - Phase I & II clinical trial manufacturing 
    - Real-time adaptive manufacturing 
    - Global supply management 
  • Commercial Manufacturing

    Product Commercial Manufacturing

    Quotient Sciences is a global player in commercial drug product manufacture of small molecule products for niche therapies including oncology and orphan drugs. Our commercial manufacturing facility located in Philadelphia is designed to handle your high-potency compounds.
    Our commercial batch size capabilities include: - Up to 500kg for solid oral dosage forms
    - Up to 350L for liquid formats using an automated filling line. In addition to manufacturing products for NDA, ANDA, MAA and JNDA registration, the Quotient team can support 505(b)(2) and CBE-30 filings.

    Process validation and registration batches: Whether you are preparing for NDA, MAA or Japanese NDA, Quotient has the expertise and regulatory approval to manufacture your validation and registration batches for the U.S., U.K., Europe and Japan.

    - Phase III and commercial drug product supply
    - High potency API handling 



  • Clinical Pharmacology

    Product Clinical Pharmacology

    When you are looking for a partner who is dedicated to Phase I trials and early clinical development, rely on Quotient Sciences for the experience and expertise to seamlessly deliver your studies with the highest quality service and speed. We accelerate your molecule from first-in-human to proof-of-concept, helping you make critical decisions earlier and faster. Whatever Phase I clinical pharmacology study you require, you can expect a fully integrated program from study design and startup to data reporting.- Phase I
    - Study types
    - Special populations
    - Human ADME
    - Regulatory affairs
    - Data Sciences
    - Modeling & simulation
    - Gamma Scintigraphy 
    - Integrating pharmacy compounding and GMP manufacturing 
  • Bioanaysis

    Product Bioanaysis

    Delivering rapid bioanalytical data in discovery – preclinical – clinical. Bioanalysis is a critical step in the drug development process.  At Quotient, we are experts in the development, validation, and application of bioanalytical assays.  
    Our dedicated team of bioanalytical chemists are globally recognized and possess over 40+ years of experience in supporting all stages of drug development, from early preclinical through to First-in-Human, Phase I and onwards to Phase II- III studies.

    - Bioanalytical assay development, validation and application - LC-MS/MS 
    - ICP-MS/MS
    - GC-MS/MS


    High resolution mass spec: - LC-TRAP-MS & LC-TOF-MS


    - Rapid turnaround time of preclinical and clinical samples
    - Even quicker with ‘Priority Analysis’ (72 hr TAT)


    - GLP & GCP accredited laboratories
    - Global compliance (FDA, EMEA, MHRA) 
    - Expertise in specialist areas
    - Insulin analogues and polypeptide drugs by LC-MS/MS
    - Elemental analysis by ICP-MS
    - Volatile drugs and biomarkers by GC/MS
    - Metabolite Identification
  • Data Sciences

    Product Data Sciences

    You need data rapidly to make crucial decisions during a study. Faster data means we can provide our customers with earlier interim data and interim PK reports for on-study dosing and formulation decisions.
    We understand on-study changes to early phase study designs and dosing are frequent and so our study strategy for study database design and reporting is built around flexibility and rapid implementation. We use eSource data collection procedures in our clinical units and a joint eSource/eCRF database. Data are available in the study database within hours of collection, ready for remote sponsor access.

    - Data Management and Database Programming Statistics and Statistical Programming
    - Pharmacokinetics
    - Medical writing
    - Standardizing study data with CDISC
    - Statistics, Pharmacokinetics and Scintigraphy

     


  • Drug Development Consulting

    Product Drug Development Consulting

    Our Drug Development Consultants work with you to design and implement successful drug development programs. With industry leading scientific expertise across a range of technical disciplines, we help customers across all stages of development, from candidate selection to commercial launch.

    Our consultants have a proven track-record of cutting across industry silos to reduce the time and cost of development.  With hands-on development experience across hundreds of drug molecules and product types, we’ll help you avoid critical pitfalls, manage risks and maximise the potential for success.
  • Global Clinical Trial Supply

    Product Global Clinical Trial Supply

    Accelerate your timeline, with flexible, on-demand delivery. We’ll design and develop your packaging, labelling and distribution strategy for Phase I, Phase II and Phase III clinical studies, so you’ll no longer have to worry about the challenge of getting your drug product to multiple sites in time for clinical trials.

    We have extensive experience developing and manufacturing drug products intended for all major routes of delivery including oral, inhaled, topical, rectal and parenteral, so you can develop and manufacture your drug products with Quotient, then seamlessly integrate into a bespoke clinical trial supply program.

QUOTIENT SCIENCES LIMITED resources

  • News Quotient Sciences acquires UK-based CDMO Arcinova

    With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide
  • Technical Data Formulation Development at Quotient

    Quotient Sciences has almost 30 years of experience developing a breadth of pharmaceutical formulations across a range of indications. Our innovative approach to formulation development integrates drug product development with clinical evaluation, combined with our experience with over 1,000 molecules at all stages of drug development. 
  • News Quotient Sciences Completes Million Dollar Pharmacy Expansion at Miami Clinic

    Miami, FL/June 22, 2020 - Quotient Sciences, a global pharmaceutical development, clinical and commercial manufacturing organization, announced today the completion of a $1 million dollar pharmacy and laboratory expansion at their Miami, FL clinical pharmacology facility. 


    The expanded pharmacy capabilities offer customers a quick and cost-effective way to start clinical testing, without the need for extensive CMC investment or API consumption at this early stage of development.
  • Technical Data Clinical Pharmacology at Quotient

    When you are looking for a partner who is dedicated to Phase I trials and early development,rely on Quotient Sciences. 

    We accelerate your molecule from first-in-human to proof-of-concept,helping you make critical decisions earlier. 
    Whatever clinical pharmacology study you require, you can expect a fully integrated program from study design to data reporting.
  • News Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

    Collaboration Expedites Human Clinical Trials for COVID-19 Drug Candidate. A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today [April 28, 2020] by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc. a privately help biotechnology company focused on the development of pharmaceutical products for treatment of infectious diseases.
  • Technical Data Global Formulation & Manufacturing Capabilities

    With over 30 years’ experience, Quotient Sciences provides full service support for small molecule non-sterile programs, from dosage formulation development through to GMP clinical trial manufacturing and commercial drug product supply.
  • News ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-19 Collaboration

    ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19.
  • Technical Data Clinical Trial Manufacturing at Quotient

    Understanding that early phase clinical testing is a pivotal milestone in the development of your drug product, Quotient offers a clinical trial manufacturing, testing and certification service designed to meet your individual requirements. 

    Our innovative method of building integrated GMP and GCP programs provides you with a streamlined, flexible approach to drug product supply that reflects your clinical study design and timeline. 


    We understand the time and cost pressures you face during early phase evaluation and work with you to ensure a rapid, seamless path from development to clinical trial supply.
  • Technical Data Commercial Manufacturing at Quotient

    Pharmaceutical commercial manufacturing - Quotient Sciences is a global player in commercial drug product manufacture of small molecule products for niche therapies including oncology and orphan drugs. 
    Our commercial manufacturing facility located in Philadelphia is designed to handle your high-potency compounds.
  • Technical Data Pediatric Development at Quotient

    Pediatric formulation and product development
    The development of acceptable, palatable pediatric formulations is a key feature within the industry today, driven by patient needs and regulatory requirements. 

    Quotient Sciences has extensive knowledge and capabilities that enable us to provide you with a unique integrated pediatric development solution.

  • Technical Data Taste Masking at Quotient

    Many drug substances are extremely bitter or have other aversive attributes,which can make developing palatable drug products extremely challenging.This is a common problem seen in medicines spanning all therapeutic areas,from antibiotics and painkillers to antihistamines and decongestants. The careful design and development of formulated oral drug products is key to ensuring patient acceptability and compliance for achieving the desired clinical outcomes.
  • Technical Data 505(b)(2) Product Development at Quotient

    Are you developing a new dosage form for an existing drug? 

    Do you need to explore a different route of administration?

    Quotient has significant experience in 505(b)(2)product development and can support you in efficiently turning your innovative ideas into successful products.Over the past several years, the FDA’s 505(b)(2)regulatory pathway has enabled the approval of a variety of differentiated dosage forms for existing molecules
  • Technical Data Translational Pharmaceutics - a Quotient Innovation

    Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing and clinical testing. The platform is unique to Quotient Sciences and has been used over the last decade by global pharmaceutical and biotech companies across over 400 drug programs.
  • Technical Data PBPK Modelling and Simulation at Quotient

    Quotient is a leading expert in the application of physiologically based pharmacokinetic (PBPK) modelling and simulation (M&S) science to drug development. 

    Using GastroPlus™ we advise our clients on the potential in vivo performance of drugs and formulations to inform product and clinical development strategies. 


    Whether working in a consultancy relationship or as part of an integrated program of work, our PBPK expertise is underpinned by our unique and extensive experience in pharmaceutics, biopharmaceutics, DMPK and clinical research.
  • Technical Data Pre-formulation & Material Sciences at Quotient

    Providing expertise to support pre-formulation development

    Our formulation development and material sciences experts have over 30 years’ experience in pre-formulation and solid state characterization.
  • Technical Data Compounding and GMP Manufacturing for Product Supply at Quotient

    Quotient Sciences provides integrated pharmacy compounding, formulation, GMP manufacturing and clinical testing solutions to help clients achieve their proof-of-concept (POC) milestone quickly, saving them precious development time and money.  

    Begin your First-in-Human (FIH) Phase I testing with a fit-for-purpose, simple pharmacy preparation, and then seamlessly transition to a scalable, solid oral GMP drug product for Phase II trials, all within one organization.
  • Technical Data Inhaled Product Development at Quotient

    With more than 30 years’ experience, Quotient is a leader in the development, manufacture and assessment of inhalation products, helping clients to accelerate molecules from first-in-human through to proof-of-concept. 

    Our integrated capabilities and vast knowledge encompasses pre-formulation sciences, formulation development, device evaluation, clinical trial manufacturing and the clinical assessment of a variety of inhaled formats for nasal and pulmonary delivery.
  • Technical Data High Potency Handling at Quotient

    High Potency Drug Development & Manufacturing

    Highly potent active pharmaceutical ingredients (HPAPIs) are becoming increasingly common in drug development pipelines, especially in the oncology sector, as researchers search for therapies with greater selectivity and pharmacological activity. However, HPAPIs present additional CMC challenges due to the containment requirements to protect both the operators and manufacturing facilities. Their production processes may also require greater precision and control due to the very small quantities of drug present in the final dosage form.
  • Technical Data Human ADME Studies at Quotient

    Whatever your requirements, Quotient Sciences can support you in the generation of clinical metabolism data for your drug development program and for NDA, MAA and global regulatory filings.
  • Technical Data First-in-human to Proof-of-Concept at Quotient

    Quotient Sciences’ Translational Pharmaceutics® approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.

    How? Quotient’s Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical testing so that drug product manufacture occurs immediately prior to dosing.Each manufacture of drug product is therefore conducted in response to emerging clinical data. This approach delivers significant benefits to the development team.
  • Technical Data Spray Drying at Quotient

    Overcoming poor drug solubility and bioavailability challenges

    Drug solubility has a significant impact on bioavailability. 70% of new chemical entities (NCEs) suffer from low aqueous solubility that can result in failure during clinical testing due to poor bioavailability. Selecting an appropriate drug formulation is imperative to the success of the program.
  • Technical Data Project Management at Quotient

    Project Management at Quotient – A True Partnership
    Quotient is an innovative drug development and manufacturing partner supporting clients from candidate selection to commercial launch. With expertise in end-to-end Project Management and integrated project teams, we make drug development easier for our customers and dramatically reduce the time and cost of getting new medicines to patients.
  • Video John McDermott, Quotient Sciences, discusses the unique benefits of Translational Pharmaceutics

    John McDermott, Executive Director, Drug Development Solutions - Quotient Sciences discusses Translational Pharmaceutics at CPhI Worldwide, and how a recent Tufts study has proven the significant savings and financial benefits for drug developers who use Translational Pharmaceutics.
  • Technical Data Formulation Strategies for Poorly Soluble Molecules at Quotient

    As the number of poorly soluble compounds continues to increase in the industry development pipeline, conventional formulation strategies may not be sufficient to achieve acceptable levels of solubility in the gastrointestinal tract and hence absorption into the systemic circulation. Scientists will need to utilize advanced formulation technologies to maximize oral bioavailability.

Recommended products